CU20200035A7 - Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2 - Google Patents

Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2

Info

Publication number
CU20200035A7
CU20200035A7 CU2020000035A CU20200035A CU20200035A7 CU 20200035 A7 CU20200035 A7 CU 20200035A7 CU 2020000035 A CU2020000035 A CU 2020000035A CU 20200035 A CU20200035 A CU 20200035A CU 20200035 A7 CU20200035 A7 CU 20200035A7
Authority
CU
Cuba
Prior art keywords
dihydro
oxo
alk
pyridin
substituted
Prior art date
Application number
CU2020000035A
Other languages
English (en)
Inventor
Luca Arista
Sylvie Chamoin
Pier Luca D´Alessandro
Mika Lindvall
Dimitrios Lizos
Nikolaus Johannes Stiefl
Sylvie Teixeira-Fouchard
Thomas Ullrich
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20200035A7 publication Critical patent/CU20200035A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La invención se refiere a compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos de Fórmula I,</p> <p>ESPACIO PARA FÓRMULA</p> <p>útiles como inhibidores selectivos de ALK-2.</p>
CU2020000035A 2017-11-24 2017-11-24 Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2 CU20200035A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2017/057389 WO2019102256A1 (en) 2017-11-24 2017-11-24 Pyridinone derivatives and their use as selective alk-2 inhibitors

Publications (1)

Publication Number Publication Date
CU20200035A7 true CU20200035A7 (es) 2021-03-11

Family

ID=60702886

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000035A CU20200035A7 (es) 2017-11-24 2017-11-24 Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2

Country Status (24)

Country Link
US (1) US11160797B2 (es)
EP (1) EP3713927B1 (es)
JP (1) JP7091455B2 (es)
KR (1) KR20200091422A (es)
CN (1) CN111433195B (es)
AU (1) AU2017440306B2 (es)
BR (1) BR112020010171A2 (es)
CA (1) CA3081651A1 (es)
CL (1) CL2020001277A1 (es)
CO (1) CO2020005885A2 (es)
CR (1) CR20200211A (es)
CU (1) CU20200035A7 (es)
DO (1) DOP2020000088A (es)
EA (1) EA202091293A1 (es)
EC (1) ECSP20026023A (es)
ES (1) ES2908252T3 (es)
IL (1) IL274722A (es)
JO (1) JOP20200127A1 (es)
MX (1) MX2020005405A (es)
PE (1) PE20201282A1 (es)
PH (1) PH12020550763A1 (es)
RU (1) RU2020120538A (es)
SG (1) SG11202003920QA (es)
WO (1) WO2019102256A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220401445A1 (en) * 2020-04-30 2022-12-22 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
CN113354631B (zh) * 2021-06-01 2022-11-18 江苏大学 一种1,3,4-噁二唑衍生物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316217B1 (en) 1992-11-17 2001-11-13 Ludwig Institute For Cancer Research Activin receptor-like kinases, proteins having serine threonine kinase domains and polynucleotides encoding same
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US8895711B2 (en) 2006-04-18 2014-11-25 The Trustees Of The University Of Pennsylvania Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
KR20090088852A (ko) 2006-09-05 2009-08-20 메다렉스, 인코포레이티드 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
EP2062048A4 (en) 2006-09-12 2009-12-02 Gen Hospital Corp METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE CELL SIGNALING AND METHODS EMPLOYING SUCH COMPOUNDS
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
MX2012012975A (es) * 2010-05-07 2013-02-26 Genentech Inc Compuestos de piridona y aza-piridona y metodos de uso de los mismos.
EP2605787B1 (en) 2010-08-20 2017-04-26 Wyeth LLC Designer osteogenic proteins
MX2013006284A (es) 2010-12-06 2013-10-28 Piramal Entpr Ltd Derivados sustituidos de imidazoquinolina.
ES2857649T3 (es) 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
EP3122355A4 (en) * 2014-03-26 2017-08-09 The Brigham and Women's Hospital, Inc. Compositions and methods for inhibiting bmp
US20170305883A1 (en) * 2014-10-01 2017-10-26 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting BMP
ES2766835T3 (es) * 2015-04-16 2020-06-15 Merck Patent Gmbh Derivados de 3-(1H-bencimidazol-2-il)-1H-piridin-2-ona

Also Published As

Publication number Publication date
RU2020120538A (ru) 2021-12-24
JP2021512850A (ja) 2021-05-20
AU2017440306B2 (en) 2021-01-28
CN111433195B (zh) 2023-04-25
RU2020120538A3 (es) 2021-12-24
ECSP20026023A (es) 2020-07-31
CA3081651A1 (en) 2019-05-31
JOP20200127A1 (ar) 2020-05-21
DOP2020000088A (es) 2020-08-31
CN111433195A (zh) 2020-07-17
WO2019102256A1 (en) 2019-05-31
EP3713927A1 (en) 2020-09-30
MX2020005405A (es) 2020-08-13
PE20201282A1 (es) 2020-11-24
CL2020001277A1 (es) 2020-11-13
EA202091293A1 (ru) 2020-11-23
US11160797B2 (en) 2021-11-02
EP3713927B1 (en) 2021-12-15
US20200360357A1 (en) 2020-11-19
AU2017440306A1 (en) 2020-05-21
SG11202003920QA (en) 2020-06-29
CO2020005885A2 (es) 2020-07-31
ES2908252T3 (es) 2022-04-28
BR112020010171A2 (pt) 2020-11-03
CR20200211A (es) 2020-06-19
JP7091455B2 (ja) 2022-06-27
PH12020550763A1 (en) 2021-04-26
KR20200091422A (ko) 2020-07-30
IL274722A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
CL2017002155A1 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CO2018013105A2 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
CY1124800T1 (el) Παραγωγο πυριδο[3,4-d]πυριμιδινης και φαρμακευτικως αποδεκτο αλας αυτου
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
CU20200051A7 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
PH12018501413A1 (en) Substituted thiohydantoin derivatives as androgen receptor antagonists
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
EA201792021A1 (ru) Ингибитор jak
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
EA201992873A1 (ru) Получение фосфатных производных
MA40302B1 (fr) Dérivés de carbazole
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MA50398A (fr) Dérivés d&#39;imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma
JOP20200030A1 (ar) مركب خماسي الحلقة
CU20200108A7 (es) Derivados de espirocromano como moduladores del receptor de acetilcolina nicotínica alfa7
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
CU20200035A7 (es) Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CU24518B1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina
CR20170058A (es) Un derivado de tetrahidropirrolo[3,4-d][1,3]tiazina como inhibidor de bace
EA201791098A1 (ru) Способ синтеза производных бензазепина
IN2013CH05394A (es)
BR112016030018A8 (pt) sal composto de heterocíclico substituído com halogênio, antagonista do receptor de lpa, composição farmacêutica e uso do referido sal